Ultrasound-guided subcostal oblique transversus abdominis plane block in canine cadavers [PDF]
Drozdzynska, M +3 more
core +2 more sources
Mucosal‐Associated Invariant T Cells in Rheumatic Diseases
Mucosal‐associated invariant T (MAIT) cells are innate‐like T cells defined by their semi‐invariant T cell receptor and restriction by the major histocompatibility complex class I–related molecule (MR1). These cells are primarily activated by microbial‐derived metabolites presented by MR1 or by cytokines.
Manon Lesturgie‐Talarek +7 more
wiley +1 more source
Thoracic spinal anaesthesia for breast surgeries: Addressing concerns and highlighting benefits. [PDF]
Paliwal NW, Khan IA.
europepmc +1 more source
Postoperative Cognitive Dysfunction after Sevoflurane Or Propofol General Anaesthesia in Combination with Spinal Anaesthesia for Hip Arthroplasty [PDF]
Yasutaka Konishi +3 more
openalex +1 more source
A Comparative Study of Spinal Anaesthesia With Hyperbaric Ropivacaine 0.75% and Hyperbaric Bupivacaine 0.5% in Hypertensive Patients Undergoing Lower Abdominal and Lower Limb Surgery. [PDF]
Singh A +4 more
europepmc +1 more source
Topical or no anaesthesia for external urethral sphincterotomy in neurogenic vesical dysfunction due to spinal injury [PDF]
M.S. Rao +7 more
openalex +1 more source
Objective This study aims to investigate the impact of nonsteroidal anti‐inflammatory drug (NSAID) intake on radiographic spinal progression in axial spondyloarthritis (axSpA), considering different NSAID types (COX‐2 inhibitors [COX2i] and nonselective NSAIDs [ns‐NSAIDs]) and disease subgroups (radiographic [r‐axSpA] and nonradiographic [nr‐axSpA ...
Murat Torgutalp +8 more
wiley +1 more source
Thoracic segmental spinal anaesthesia: expanding applications while keeping it safe. [PDF]
Paliwal NW, Khan IA.
europepmc +1 more source
Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis
Background Transition from long‐term denosumab to PTH‐analogs or romosozumab might expose patients to the risk of the so‐called rebound phenomenon. Adding romosozumab to denosumab might represent an option in patients experiencing a fracture while on denosumab.
Giovanni Adami +10 more
wiley +1 more source

